WP-1048 is under clinical development by Worg Pharmaceuticals Hangzhou and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect WP-1048’s likelihood of approval (LoA) and phase transition for Grass Pollen Allergy took place on 29 Oct 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their WP-1048 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
WP-1048 a recombinant protein (hypoallergenic grass pollen vaccine) is under development for the treatment of grass-pollen allergy. It is a third generation grass pollen allergy. It is a mixture of four recombinant proteins consists of BM321, BM322, BM325 and BM326. It is administered by subcutaneous route. The drug candidate is developed based on peptide carrier fusion protein technology (PCFiT).
Worg Pharmaceuticals Hangzhou overview
Worg Pharmaceuticals is a clinical-stage biopharmaceutical company developing new treatments for allergy and other diseases with high unmet medical needs and considerable commercial potential. It is headquartered in Hangzhou, Zhejiang, China.
Quick View WP-1048 LOA Data
|Highest Development Stage|